Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

All Conditions

Rare Diseases

Laryngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Laryngeal Diseases

Respiratory Tract Diseases

Respiratory Tract Neoplasms

Otorhinolaryngologic Diseases

Laryngeal Cancer

status from radical operation to follow-up

The surgery treatment selection was based on the American Joint Committee on Cancer stage both of the primary and of the recurrence, as well as on patterns of local spread that were not included in the T classification and on the general condition and preferences of each patient.

Radical Operation

Genglong Liu

Xiaojun Tan

Advanced laryngeal squamous cell carcinoma (SCC) remains a highly morbid and fatal disease despite aggressive interventions. Mortality is high in this cohort: laryngeal cancer affects over 13 000 patients in the United States, with over 3500 deaths annually.The results of the Veterans Affairs Cooperative Studies Program Laryngeal Cancer Trial and subsequent studies demonstrated similar overall survival (OS) rates for organ preservation protocols involving radiotherapy (RT) or chemoradiotherapy (CRT) when compared to surgery, with the benefit of preserving the larynx in a large majority of patients. As such, the use of RT or CRT has become the predominant initial intervention for patients with laryngeal SCC.However, the prognosis of recurrent and persistent laryngeal SCC is particularly dire.In this study,the investigators sought to identify preoperative predictors of survival for patients with recurrent or persistent laryngeal SCC in order to set patient expectations and address modifiable risk factors. Identification of predictors of survival may also identify patients who could benefit from novel therapeutic agents in a neo/adjuvant fashion. Herein,we examine a cohort of patients with recurrent or persistent laryngeal SCC after definitive RT/CRT who has undergone total laryngectomy in order to identify potential preoperative predictors of clinical outcomes.

Demographic, clinical, and survival data were abstracted. Death was verified via medical records and the social security death index. Primary outcome measures were OS (time from salvage laryngectomy to death from any cause), disease-specific survival (DSS; time from salvage laryngectomy to death from recurrent/persistent laryngeal SCC), and DFS (time from salvage laryngectomy to laryngeal SCC recurrence)

Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer

Development and Validation of Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer: a Single-institutional Study

time from laryngectomy to death from any cause

First Affiliated Hospital, Sun Yat-Sen University

Principal Investigator

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Thoracic Neoplasms

Lung Diseases

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Vinorelbine

Cisplatin

Erlotinib Hydrochloride

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tubulin Modulators

Antimitotic Agents

Tyrosine

Erlotinib

cis-platinum

Changli Wang

This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) 19 or 21 exon mutation treated Erlotinib vs NP chemotherapy as adjuvant therapy.

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

A Prospective, Open-labelled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation NSCLC Patients With EGFR19 or 21 Exon Mutation

2-year disease free survival rate is defined as the estimation percentage of disease free survival patients with study treatment at 2-year.

Disease free survival is defined as the time from randomization to disease recurrence or death which comes first.

Overall survival is defined as the time from randomization to death.

The score of Functional Assessment of Cancer Therapy - Lung (FACT-L) subscale and Lung Cancer Symptom Scale (LCSS)

Roche Pharma AG

Tianjin Medical University Cancer Institute and Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer	NCT03747783	Laryngeal Cance...	Radical Operati...	18 Years - 75 Years	First Affiliated Hospital, Sun Yat-Sen University
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation	NCT01683175	Non-small Cell ...	Erlotinib cis-platinum Vinorelbine	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation	NCT01683175	Non-small Cell ...	Erlotinib cis-platinum Vinorelbine	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital

Spots Global Cancer Trial Database for radical operation